ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bob Langer, a professor at the Massachusetts Institute of Technology and serial entrepreneur, has teamed up with fellow MIT engineer Giovanni Traverso and former Sherlock Biosciences CEO Rahul Dhanda to launch a start-up called Syntis Bio. The firm’s lead compound, SYNT-101, is a daily pill that coats receptors in the upper part of the intestine, blocking nutrient absorption to help patients lose weight. Syntis also sees potential applications in metabolic diseases like homocystinuria and maple syrup urine disease, both of which are related to the body’s inability to process certain amino acids. Syntis has so far raised $15.5 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X